A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry

Alice Jane Owen, Jean Marie Spinks, Adam David Meehan, T Robb, Melissa Hardy, D Kwasha, John H Wlodarczyk, Christopher Michael Reid

Research output: Contribution to journalArticleResearchpeer-review

21 Citations (Scopus)
Original languageEnglish
Pages (from-to)235 - 243
Number of pages9
JournalJournal of Medical Economics
Issue number2
Publication statusPublished - 2008

Cite this